Evidence map›Paper›PMID 18158588›Full record

ArticleMolecular and cellular biochemistry2008

Atorvastatin accelerates extracellular nucleotide degradation in human endothelial cells.

Lana Osman, Mohamed Amrani, Charles Ilsley, Magdi H Yacoub, Ryszard T Smolenski

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Lana OsmanHeart Science Centre, Imperial College at Harefield Hospital, Harefield, Middlesex UB9 6JH, UK.
Mohamed Amrani
Charles Ilsley
Magdi H Yacoub
Ryszard T Smolenski
Harefield Hospital · GBRoyal Brompton & Harefield NHS Foundation Trust · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

HMG-CoA reductase inhibitors (statins) exert pleiotropic effects in the cardiovascular system beyond its cholesterol-lowering action. We aimed to investigate how atorvastatin affects extracellular nucleotide degradation in human endothelial cells, as increased activity of this pathway would facilitate conversion of pro-inflammatory nucleotides into anti-inflammatory adenosine. Primary cultures of human endothelial cells were treated with 1 microM, 10 microM and 100 microM atorvastatin for 24 h. Enzyme assays were performed as well as intact cell studies, to evaluate capacity of cells to degrade ATP to adenosine. Atorvastatin significantly increased ATP breakdown and adenosine formation in the medium of intact cells in a dose-dependent manner. The activities of ATPase, ADPase and ecto-5'-nucleotidase (eN) in cell homogenates following Atorvastatin treatment were also increased while no change was observed in the lactate dehydrogenase activity. We suggest a new mechanism of protective effect of atorvastatin by activation of endothelial enzymes involved in extracellular nucleotide degradation in human endothelial cells.

Indexed as

5'-NucleotidaseAdenosine MonophosphateAdenosine TriphosphateAtorvastatinCell ExtractsCells, CulturedEndothelial CellsExtracellular SpaceHeptanoic AcidsHumansL-Lactate DehydrogenaseMevalonic AcidPolyisoprenyl PhosphatesPyrrolesUmbilical Veins5'-NucleotidaseAdenosine MonophosphateAdenosine TriphosphateAtorvastatinCell Extractsgeranylgeranyl pyrophosphateHeptanoic AcidsL-Lactate DehydrogenaseMevalonic AcidPolyisoprenyl PhosphatesPyrroles

Identifiers

PMID18158588
OpenAlexW2015737075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.